Plus Therapeutics Inc. (NASDAQ: PSTV) and RadioMedix Inc. Enter Strategic Commercial Agreement For Radiopharmaceuticals Production

Plus Therapeutics Inc. (NASDAQ: PSTV) has announced a commercial agreement with RadioMedix Inc. for the production of its radiopharmaceuticals. 

Plus Therapeutics enters agreement with RadioMedix 

Marc Hedrick, the CDEO and President of Plus Therapeutics, said, “RadioMedix is a global leader in developing and producing GMP radiopharmaceutical products. This strategic partnership substantially supports our efforts to have fully compliant 186RNL available by mid-2022 for a potential Phase 2/3 clinical study in adults with recurrent glioblastoma (GBM).”

According to the agreement, RadioMedix will manufacture cGMP product candidates that meet the US FDA’s necessary requirements and other regulatory bodies. The strategic collaborations additionally secure 186RNL’s commercial supply chain and expand to other future products produced through the RNL platform. 

RadioMedix CEO and Chairman Ebrahim S. Delpassand said, “We are very excited to be the GMP manufacturing arm of Plus Therapeutics and participate in the development of 186RNL, a promising radiotherapeutic for central nervous system tumors. Our investment in state-of-the-art facilities for radiopharmaceutical manufacturing and highly trained experts emphasizes our commitment to delivering positive customer experiences across all phases of radiopharmaceutical development and commercial manufacturing.”

Plus Therapeutics’ nanotech platform is vital in the development of cancer therapies. 

The company is developing 186RNL  for recurrent GBM, pediatric brain cancer, and leptomeningeal metastases treatment. Plus Therapeutics has designed 186RNL to effectively, conveniently, and safely deliver enhanced radiation doses to the central nervous and rare tumors. Enrolment is currently ongoing for recurrent GBM patients in the US in the NIH-supported Multi-site ReSPECT-GBM Phase one dose-finding clinical study. 

Also, Plus Therapeutics is focused on creating proprietary, targeted radiotherapies with nonliposome-encapsulated radionuclides to treat difficult-to-treat and rare cancers. Drug development is central to Plus Therapeutics’ proprietary nanotech platform that is designed to develop, produce, and commercialize several therapies for rare cancers and other difficult to treat diseases. In addition, the platform facilitates new delivery approaches and the formulation of effective and safe injectable treatments.